Research Based on Gut Microbiota Metagenomics for Prevention of Chronic Liver Disease
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 3,240
- 试验地点
- 1
- 主要终点
- Fecal DNA
研究概览
简要总结
Gut microbiota modulation has effect on chronic liver disease
详细描述
Chronic liver disease has been known as a disease of the liver which lasts over a period of 6-month. It consists of inflammation, hepatitis, cirrhosis, hepatocellular carcinoma.
Gut microbiota plays an important roles in the chronic liver disease. It can suppress the progression of the liver disease by moulation gut microbiota.
The investigators are still evaluating the effect of gut microbiota on the liver disease.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 31 Years 至 82 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Normal : AST or ALT level < 50IU/L, BMI < 25
- •Liver disease : AST or ATL level ≥ 50IU/L, BMI ≥ 25
- •Patients hospitalized with chronic liver disease (viral hepatitis, alcoholic liver disease, non-alcoholic liver disease, cirrhosis, liver cancer)
排除标准
- •Normal : AST or ATL level ≥ 50IU/L, BMI ≥ 25
- •Liver disease : AST or ALT level < 50IU/L, BMI < 25
- •If the patient refuses
结局指标
主要结局
Fecal DNA
时间窗: 10 years
Compare the species and proportions of the gut microbiome
BMI
时间窗: 10 years
Compare the body mass index
Liver enzyme
时间窗: 10 years
Compare the liver enzyme level
次要结局
未报告次要终点
研究者
Ki Tae Suk
Proffesor
Chuncheon Sacred Heart Hospital
